# Eileen Farrelly

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/eileen-farrelly/

## Facts

| Field | Value |
| --- | --- |
| Citations | 934 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 19 |
| i10-index | 27 |
| Last Known Institution | Vencore (United States) |
| OpenAlex ID | https://openalex.org/A5040067170 |
| Works | 91 |

## Researcher papers

- [Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma](https://scholariq.org/papers/randomized-clinical-trial-representativeness-and-outcomes-in-real-world-patients/)
- [Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis](https://scholariq.org/papers/cardiometabolic-comorbidities-readmission-and-costs-in-schizophrenia-and-bipolar/)
- [Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States](https://scholariq.org/papers/prolonged-duration-of-therapy-is-associated-with-improved-survival-in-patients/)
- [Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd](https://scholariq.org/papers/real-world-outcomes-and-factors-impacting-treatment-choice-in-relapsed-and-or/)
- [The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims](https://scholariq.org/papers/the-prevalence-and-burden-of-systemic-lupus-erythematosus-in-a-medicare/)
- [The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies](https://scholariq.org/papers/the-impact-of-age-and-comorbidities-on-practice-patterns-and-outcomes-in/)
- [Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States](https://scholariq.org/papers/economic-burden-of-elderly-patients-with-acute-myeloid-leukemia-treated-in/)
- [Impact of COPD Exacerbation Frequency on Costs for a Managed Care Population](https://scholariq.org/papers/impact-of-copd-exacerbation-frequency-on-costs-for-a-managed-care-population/)
- [Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US](https://scholariq.org/papers/real-world-comparative-effectiveness-of-triplets-containing-bortezomib-b/)
- [Venous thromboembolism after orthopedic surgery: Implications of the choice for prophylaxis](https://scholariq.org/papers/venous-thromboembolism-after-orthopedic-surgery-implications-of-the-choice-for/)
- [Real-world treatment utilization and economic implications of lupus nephritis disease activity in the United States](https://scholariq.org/papers/real-world-treatment-utilization-and-economic-implications-of-lupus-nephritis/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Acute Myeloid Leukemia Research](https://scholariq.org/topics/acute-myeloid-leukemia-research/)
- [Venous Thromboembolism Diagnosis and Management](https://scholariq.org/topics/venous-thromboembolism-diagnosis-and-management/)
- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)

## Researcher university

- [Vencore (United States)](https://scholariq.org/institutions/vencore-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.